US and UK Strike Zero-Tariff Pact on Prescription Drugs.
Britain and America have concluded a landmark commercial pact that will ensure zero levies on British pharmaceutical exports entering the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to boost funding on medicines through the NHS. This commitment guarantees that import taxes on these vital goods will remain at nothing for a duration of 36 months.
This development follows earlier statements to significantly raise import taxes on branded drug products, with increases floated as high as 100%.
"This arrangement between the UK reinforces the global environment for new treatments and establishes much-needed balance to U.S.–U.K. medicine commerce," a statement said.
Economic Importance
Medicines represent one of the Britain's biggest exports to the United States, which is easily the largest buyer for large companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period leading up to the third quarter, the UK shipped pharmaceutical products worth billions to the US. This figure represented 17.4% of total UK exports in that span.
"This deal protects jobs, increases funding and paves the way for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary commented.
Specific NHS Changes
The deal includes several notable commitments from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a target to raise total health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Payback Limit: The sum drug companies must pay back to the NHS to stay within budget will be restricted at 15%. In the past, repayments topped 20%.
Recent Tensions
The deal follows a ongoing tension between the pharmaceutical industry and the ministers over medicine costs and approval rates.
These tensions were intensified by claims that American consumers were paying a premium for the same drugs than consumers in the other developed nations.
Recently, several significant manufacturing plans in the UK have been paused or cancelled, while multi-billion-dollar investments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS must spend more on drugs, noting that its spending on drugs had decreased as a share of its overall budget over the past decade.
